1-17 of 17
Monika Dlugosz-Danecka
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study

Meghan C. Thompson, Seema A. Bhat, Wojciech Jurczak, Krish Patel, Nirav N. Shah, Jennifer A. Woyach, Catherine C. Coombs, Toby A. Eyre, Michal Danecki, Monika Dlugosz-Danecka, Neil Bailey, Joanna M. Rhodes, Nicole Lamanna, Andrew H. Lipsky, Jeffrey Jensen, Adam Kidwell, Eytan M. Stein, Monica Shah, Jennifer R. Brown, Andriy Derkach, Anthony R. Mato, Lindsey Roeker
Journal: Blood
Blood (2024) 144 (Supplement 1): 1870.
https://doi.org/10.1182/blood-2024-194748
Published: 2024
Journal Articles

The Outcome of the First-Line Therapy of Patients with Follicular Lymphoma during COVID-19 Pandemic. a Real-World Data from the Polish Lymphoma Research Group (PLRG)

Ewa Paszkiewicz-Kozik, Monika Palka, Malgorzata Debowska, Marcin Szymanski, Agnieszka Konska, Elzbieta Kalicinska, Agata Tyczynska, Joanna Drozd-Sokolowska, Agnieszka Giza, Ryszard Swoboda, Anna Paulina Dabrowska-Iwanicka, Marta Morawska, Justyna Owczarek-Kaczmarek, Lukasz Bolkun, Anna Kopinska, Ewa Wasik-Szczepanek, Dominika Maksylewicz, Anna Wisniewska, Lukasz Targonski, Edyta Subocz, Pawel Steckiewicz, Katarzyna Domanska-Czyz, Beata Ostrowska, Monika Swierkowska, Jacek Krzanowski, Agnieszka Druzd-Sitek, Ewa Mroz-Zycinska, Joanna Romejko-Jarosinska, Iwona Hus, Monika Dlugosz-Danecka, Ewa Lech-Maranda, Tomasz Wrobel, Jan M. Zaucha, Jan Walewski
Journal: Blood
Blood (2023) 142 (Supplement 1): 1679.
https://doi.org/10.1182/blood-2023-186945
Published: 2023
Journal Articles

Safety and Early Efficacy of Obinutuzumab in Combination with Chemotherapy in Treatment Naive Patients with Follicular Lymphoma - Report of Polish Lymphoma Research Group (PLRG)

Ewa Paszkiewicz-Kozik, Iwona Hus, Monika Palka, Malgorzata Debowska, Agnieszka Konska, Martyna Kotarska, Agata Tyczynska, Monika Joks, Maja Twardosz, Agnieszka Giza, Ewa Wasik-Szczepanek, Elzbieta Kalicinska, Anna Wisniewska, Marta Morawska, Joanna Romejko-Jarosinska, Barbara Lewicka, Lukasz Targonski, Michal Osowiecki, Lidia Poplawska, Marcin Szymanski, Kamila Kruczkowska-Taranowicz, Joanna Drozd-Sokolowska, Ryszard Swoboda, Katarzyna Domanska-Czyz, Beata Ostrowska, Monika Swierkowska, Anna Paulina Dabrowska-Iwanicka, Agnieszka Druzd-Sitek, Robert Konecki, Anna Borawska, Monika Dlugosz-Danecka, Ewa Lech-Marańda, Jan Walewski
Journal: Blood
Blood (2021) 138 (Supplement 1): 4525.
https://doi.org/10.1182/blood-2021-145534
Published: 2021
Journal Articles

Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

Ryan Jacobs, Wojciech Jurczak, Ian W. Flinn, Sebastian Grosicki, Krzysztof Giannopoulos, Tomasz Wróbel, Syed F. Zafar, Jennifer L. Cultrera, Suman Kambhampati, Alexey V. Danilov, John M. Burke, Jerome Goldschmidt, Douglas F. Beach, Scott F. Huntington, Javier Pinilla Ibarz, Jeff P. Sharman, Tanya Siddiqi, Danielle M. Brander, Mazyar Shadman, John M. Pagel, Monika Dlugosz-Danecka, Nilanjan Ghosh, Kathryn S. Kolibaba, Peter Sportelli, Hari P. Miskin, Owen A. O'Connor, Michael S. Weiss, John G. Gribben
Journal: Blood
Blood (2021) 138 (Supplement 1): 3726.
https://doi.org/10.1182/blood-2021-147460
Published: 2021
Journal Articles

The Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 As Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-Cell Malignancies

Chan Yoon Cheah, Wojciech Jurczak, Masa Lasica, Tomasz Wróbel, Stanley Cheung, Jan Walewski, Krzysztof Giannopoulos, Costas K. Yannakou, Katharine L Lewis, Monika Dlugosz-Danecka, Hari P. Miskin, Alejandro D. Ricart, Owen A. O'Connor, Constantine S. Tam
Journal: Blood
Blood (2021) 138 (Supplement 1): 1549.
https://doi.org/10.1182/blood-2021-145911
Published: 2021
Journal Articles

A Phase 1, Open-Label Study of MGD013, a Bispecific DART ® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jie Wang, MD, Adam S. Asch, MD, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA, Andrew Weickhardt, MBBS(Hons) FRACP DMedSc, Monika Tomaszewska-Kiecana, Monika Dlugosz-Danecka, MD PhD, Halyna Pylypenko, MD, Shakeela Bahadur, MD, Susanna Ulahannan, MD MMed, Janine Koucheki, Jichao Sun, PhD, Hua Li, Francine Chen, MD, Xiaoyu Zhang, John Muth, MS, Patrick Kaminker, PhD, Paul Moore, PhD, Bradley James Sumrow, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–22.
https://doi.org/10.1182/blood-2020-139868
Published: 2020
Journal Articles

Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

David J. Straus, MD, Monika Dlugosz-Danecka, MD PhD, Joseph M. Connors, MD, Árpád Illés, MD PhD, Marco Picardi, MD, Ewa Lech-Marańda, MD PhD, Tatyana Feldman, Piotr Smolewski, MD PhD, Kerry J. Savage, MDMSc, Nancy L. Bartlett, MD, Jan Walewski, MD, Radhakrishnan Ramchandren, MD, Pier Luigi Zinzani, MD, Martin Hutchings, MD PhD, Javier Munoz, MD, Won Seog Kim, MD PhD, Ranjana Advani, MD, Stephen M. Ansell, MD PhD, Anas Younes, Andrea Gallamini, Rachael Liu, PhD, Meredith Little, MPH, Keenan Fenton, Michelle A. Fanale, MD, John A. Radford, MD FMedSci
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–28.
https://doi.org/10.1182/blood-2020-137089
Published: 2020
Journal Articles

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Wojciech Jurczak, MD PhD, Ryan W. Jacobs, MD, Sebastian Grosicki, MD PhD, Krzysztof Giannopoulos, MD PhD, Tomasz Wrobel, MDPhD, Syed F. Zafar, MD, Jennifer L. Cultrera, MD, Suman Kambhampati, MD, Alexey Danilov, MD, John M. Burke, MD, Jerome Goldschmidt, MD, Douglas F. Beach, MD, Scott F. Huntington, MD MPH, Javier Pinilla Ibarz, MD PhD, Jeff P Sharman, MD, Tanya Siddiqi, MD, Danielle M. Brander, MD, John M. Pagel, MDPhD, Kathryn S. Kolibaba, MD, Monika Dlugosz-Danecka, MD PhD, Nilanjan Ghosh, MD PhD, Peter Sportelli, BS, Hari P. Miskin, MSc, Owen A. O'Connor, MD PhD, Michael S. Weiss, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–39.
https://doi.org/10.1182/blood-2020-134783
Published: 2020
Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study

Michael Wang, MD, Simon Rule, MD PhD, Pier Luigi Zinzani, MD, Andre H. Goy, MD, Rene-Olivier Casasnovas, MD, Stephen D. Smith, MD, Gandhi Laurent Damaj, MD PhD, Jeanette K. Doorduijn, MD PhD, Thierry Lamy, Franck Morschhauser, MD PhD, Carlos Panizo, MD PhD, Bijal Shah, MD, Andrew Davies, MD PhD, Richard Eek, FRACP., Jehan Dupuis, MD, Eric Jacobsen, MD, Arnon P. Kater, MDPhD, Steven Le Gouill, MD PhD, Lucie Oberic, MD, Tadeusz Robak, MDPhD, Preetesh Jain, MBBS,MDDM,PhD, Graham Brock, PhD, Priti Patel, MD, Lin Tao, Monika Dlugosz-Danecka, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-134824
Published: 2020
Journal Articles

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Clinical Trials & Observations
David J. Straus, Monika Długosz-Danecka, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech-Maranda, Tatyana Feldman, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Jan Walewski, Radhakrishnan Ramchandren, Pier Luigi Zinzani, Martin Hutchings, Joseph M. Connors, John Radford, Javier Munoz, Won Seog Kim, Ranjana Advani, Stephen M. Ansell, Anas Younes, Harry Miao, Rachael Liu, Keenan Fenton, Andres Forero-Torres, Andrea Gallamini
Journal: Blood
Blood (2020) 135 (10): 735–742.
https://doi.org/10.1182/blood.2019003127
Published: 2020
Includes: Supplemental data
Journal Articles

Improved Treatment Outcomes for Patients with Hodgkin Lymphoma Relapsing after Autologous Hematopoietic Stem Cell Transplantation in the Brentuximab Vedotin Era - the Real-Life Report from the Polish Lymphoma Research Group

Anna Czyz, MD PhD, Anna Lojko-Dankowska, MD PhD, Agnieszka Giza, MD PhD, Monika Dlugosz-Danecka, MD PhD, Wojciech Jurczak, MD PhD, Joanna Romejko-Jarosinska, MD PhD, Ewa Paszkiewicz, MD PhD, Justyna Rybka, MD PhD, Joanna Drozd-Sokolowska, MD PhD, Edyta Subocz, MD PhD, Tomasz Czerw, MD PhD, Barbara Nasilowska-Adamska, MD PhD, Agnieszka Kolkowska, MD PhD, Manko Joanna, MD PhD, Dorota Hawrylecka, MD PhD, Wanda Knopinska-Posluszny, MD PhD, Szymanska Agata, MD PhD, Lidia Gil, MD PhD, Mieczyslaw Komarnicki, MD PhD, Marek Hus, MD PhD, Jan Walewski, MD PhD, Sebastian Giebel, MD PhD, Tomasz Wrobel, MD PhD, Jan Zaucha, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5276.
https://doi.org/10.1182/blood-2019-130484
Published: 2019
Journal Articles

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study

Nancy L. Bartlett, MD, David J. Straus, MD, Monika Dlugosz-Danecka, MD PhD, Sergey Alekseev, PhD, Arpad Illes, MD, Ewa Lech-Maranda, MD PhD, Tatyana A. Feldman, MD, Piotr Smolewski, MD PhD, Kerry J Savage, BSc, MD MSc, Jan Walewski, MD PhD, Radhakrishnan Ramchandren, MD, Pier Luigi Zinzani, MD PhD, Martin Hutchings, MD PhD, Joseph M. Connors, MD, John Radford, Javier Munoz, MD MS, FACP, Won-Seog Kim, MD PhD, Ranjana H Advani, MD, Stephen M Ansell, MD PhD, Anas Younes, MD, Andrea Gallamini, MD, Harry Miao, MD, Rachael Liu, PhD, Keenan Fenton, Andres Forero-Torres, MD, Marco Picardi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4026.
https://doi.org/10.1182/blood-2019-124116
Published: 2019
Journal Articles

Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

Andrew M. Evens, DO, MSc, Joseph M. Connors, MD, Anas Younes, MD, Stephen M. Ansell, MD PhD, Won Seog Kim, MD PhD, John Radford, MD FRCP, Tatyana A. Feldman, MD, Joseph Tuscano, Kerry J Savage, BSc, MD MSc, Yasuhiro Oki, MD, Andrew P. Grigg, MBBS, FRACP, FRCPA, MD, Christopher Pocock, MD PhD, Monika Dlugosz-Danecka, MD PhD, Keenan Fenton, Gerald Engley, PharmD, Rachael Liu, PhD, Harry Miao, MD, Hina Jolin, Pharm D, Ashish Gautam, PhD MBA, Andrea Gallamini, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1618.
https://doi.org/10.1182/blood-2018-99-112178
Published: 2018
Journal Articles

Brentuximab Vedotin Alone and in Combination with Bendamustine As Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: Multicentre Experience of the Polish Lymphoma Research Group (PLRG)

Anna Czyz, MD PhD, Anna Lojko-Dankowska, Monika Joks, MD, Mieczyslaw Komarnicki, MD PhD, Monika Dlugosz-Danecka, MD PhD, Wojciech Jurczak, Justyna Rybka, MD PhD, Tomasz Wrobel, MD PhD, Ewa Paszkiewicz, Jan Walewski, MD, Dorota Hawrylecka, Joanna Drozd-Sokolowska, MD PhD, Edyta Subocz, Szymanska Agata, Magdalena Witkowska, Piotr Smolewski, MD PhD, Agnieszka Kolkowska, Ewa Lech Maranda, Wanda Knopinska-Posluszny, Sebastian Giebel, Jan Zaucha, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5375.
https://doi.org/10.1182/blood-2018-99-116610
Published: 2018
Journal Articles

Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study

Joseph M. Connors, MD, Anas Younes, MD, Andrea Gallamini, MD, Stephen M. Ansell, MD PhD, Won-Seog Kim, Ranjana H Advani, MD, Nancy L. Bartlett, MD, David J. Straus, MD, Anna Sureda, MD, Martin Hutchings, MD PhD, Monika Dlugosz-Danecka, MD PhD, Gerald Engley, PharmD, Keenan Fenton, Rachael Liu, PhD, Harry Miao, MD, Hina Jolin, Pharm D, Ashish Gautam, PhD MBA, John Radford, MD FRCP
Journal: Blood
Blood (2018) 132 (Supplement 1): 2904.
https://doi.org/10.1182/blood-2018-99-118828
Published: 2018
Journal Articles

Resolution of Peripheral Neuropathy (PN) in Patients Who Received A+AVD or ABVD in the Phase 3 ECHELON-1 Trial

John Radford, MD FRCP, Joseph M. Connors, MD, Anas Younes, MD, Andrea Gallamini, MD, Stephen M. Ansell, MD PhD, Won Seog Kim, MD PhD, Ajay K. Gopal, MD, Mark S Kaminski, MD, June Won Cheong, MDPhD, Ian W. Flinn, MD PhD, Nagesh Kalakonda, MD, Ruth Pettengell, MD, Monika Dlugosz-Danecka, MD PhD, Gerald Engley, PharmD, Keenan Fenton, Rachael Liu, PhD, Indra Purevjal, Harry Miao, MD, Ashish Gautam, PhD MBA, John Kuruvilla, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2921.
https://doi.org/10.1182/blood-2018-99-111893
Published: 2018
Journal Articles

Subcutaneous Compared to Intravenous Administration of Rituximab Plus CHOP in Patients with Diffuse Large B-Cell Lymphoma — a Study By the Polish Lymphoma Research Group

Ewa Paszkiewicz-Kozik, Monika Dlugosz-Danecka, MD PhD, Paweł J. Robak, MD, Elżbieta Wojciechowska-Lampka, MD, Monika Swierkowska-Czeneszew, MD, Joanna Tajer, MD PhD, Joanna Romejko-Jarosinska, MD PhD, Katarzyna Domanska-Czyz, MD, Marcin Szymanski, MD, Marta Morawska, MD, Lukasz Targonski, MD, Michal Osowiecki, MD, Beata Ostrowska, MDPhD, Anna Paulina Dabrowska-Iwanicka, MD PhD, Jan Walewski, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5217.
https://doi.org/10.1182/blood.V130.Suppl_1.5217.5217
Published: 2017